CA2397961C - Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase - Google Patents

Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase Download PDF

Info

Publication number
CA2397961C
CA2397961C CA002397961A CA2397961A CA2397961C CA 2397961 C CA2397961 C CA 2397961C CA 002397961 A CA002397961 A CA 002397961A CA 2397961 A CA2397961 A CA 2397961A CA 2397961 C CA2397961 C CA 2397961C
Authority
CA
Canada
Prior art keywords
pyrido
pyrimidin
urea
phenylamino
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002397961A
Other languages
English (en)
Other versions
CA2397961A1 (fr
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata Nagendra Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CA2397961A1 publication Critical patent/CA2397961A1/fr
Application granted granted Critical
Publication of CA2397961C publication Critical patent/CA2397961C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des composés de la formule: dans laquelle R<2>, R<7>, R<13>, R<14> et R15 sont indépendamment hydrogène, ou alkyle inférieur substitué (non substitué), alcényle inférieur substitué (non substitué), alkynyle inférieur substitué (non substitué), ou (CH2)nR<12> substitué (non substitué); R<5> est halogène, cyano, nitro, -R<9>, -NR<9>R<10>, -OR<9>; R<6> est halogène, cyano, nitro, -R<9>, -NR<9>R<10>, -OR<9>, -CO2R<9>, -COR<9>, -CONR<9>R<10>, -NR<9>COR<10>, alcényle inférieur substitué (non substitué) ou alkynyle inférieur substitué (non substitué); R<8> est -CO2R<13>, -COR<13>, -CONR<13>R<14>, -CSNR<13>R<14>, -C(NR<13>)NR<14>R<15>, -SO3R<13>, -SO2R<13>, -SO2NR<13>R<14>, -PO3R<13>R<14>, -POR<13>R<14>, -PO(NR<13>R<14>)2; R<9> et R<10> sont indépendamment hydrogène ou alkyle inférieur substitué (non substitué); R<11> est un hétéroaryle ou un groupe hétérocyclique; R<12> est un cycloalkyle, un hétérocyclique, un aryle ou un groupe hétéroaryle ; et n représente 0,1,2, ou 3. Ces composées et leurs compositions pharmaceutiques s'avèrent utiles pour traiter des troubles de prolifération cellulaire, tels que le cancer et la resténose. Lesdits composés sont des inhibiteurs efficaces des kinases cyclino-dépendantes (cdks) et des kinases liées au facteur de croissance.
CA002397961A 2000-01-25 2001-01-23 Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase Expired - Fee Related CA2397961C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
US60/178,261 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (fr) 2000-01-25 2001-01-23 Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase

Publications (2)

Publication Number Publication Date
CA2397961A1 CA2397961A1 (fr) 2001-08-02
CA2397961C true CA2397961C (fr) 2008-08-26

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002397961A Expired - Fee Related CA2397961C (fr) 2000-01-25 2001-01-23 Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase

Country Status (34)

Country Link
EP (1) EP1254137A1 (fr)
JP (1) JP4047010B2 (fr)
KR (1) KR20020065939A (fr)
CN (1) CN1395578A (fr)
AP (1) AP2002002586A0 (fr)
AR (1) AR030044A1 (fr)
AU (1) AU2542501A (fr)
BG (1) BG106850A (fr)
BR (1) BR0107751A (fr)
CA (1) CA2397961C (fr)
CO (1) CO5261549A1 (fr)
CR (1) CR6706A (fr)
CZ (1) CZ20022475A3 (fr)
DZ (1) DZ3266A1 (fr)
EA (1) EA200200643A1 (fr)
EE (1) EE200200405A (fr)
GT (1) GT200100016A (fr)
HN (1) HN2001000013A (fr)
HU (1) HUP0204141A3 (fr)
IL (1) IL150545A0 (fr)
IS (1) IS6443A (fr)
MA (1) MA26868A1 (fr)
MX (1) MXPA02007221A (fr)
NO (1) NO20023527L (fr)
OA (1) OA12161A (fr)
PA (1) PA8510701A1 (fr)
PE (1) PE20011066A1 (fr)
PL (1) PL356802A1 (fr)
SK (1) SK10632002A3 (fr)
SV (1) SV2002000294A (fr)
TN (1) TNSN01014A1 (fr)
WO (1) WO2001055147A1 (fr)
YU (1) YU50402A (fr)
ZA (1) ZA200205879B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2404603A1 (fr) 2000-10-23 2012-01-11 Glaxosmithkline LLC Nouveaux composés 8H-pyrido[2,3-d]pyrimidin-7-one trisubstituté pour le traitement des maladies faisant intervenir les kinases CSBP/p38.
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7550589B2 (en) * 2004-09-21 2009-06-23 Hoffman-La Roche Inc. 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
EP1865959A2 (fr) 2005-03-25 2007-12-19 Glaxo Group Limited Procede de preparation de derives pyridoý2,3-d¨pyrimidin-7-one et 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Composes pyrido [2, 3-d] pyrimidine-2, 4-diamine utilises comme inhibiteurs de ptp1b
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (fr) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
EP3733184B1 (fr) * 2013-03-14 2023-08-30 Icahn School of Medicine at Mount Sinai Composés de pyrimidine pour l'utililisation dans la traitment de cancer
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (es) * 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid

Also Published As

Publication number Publication date
TNSN01014A1 (fr) 2005-11-10
NO20023527L (no) 2002-09-10
PL356802A1 (en) 2004-07-12
CZ20022475A3 (cs) 2003-03-12
AP2002002586A0 (en) 2002-09-30
JP2003523357A (ja) 2003-08-05
WO2001055147A1 (fr) 2001-08-02
EA200200643A1 (ru) 2002-12-26
CN1395578A (zh) 2003-02-05
EP1254137A1 (fr) 2002-11-06
YU50402A (sh) 2005-11-28
MA26868A1 (fr) 2004-12-20
CA2397961A1 (fr) 2001-08-02
NO20023527D0 (no) 2002-07-24
OA12161A (en) 2006-05-08
KR20020065939A (ko) 2002-08-14
BG106850A (bg) 2003-02-28
CO5261549A1 (es) 2003-03-31
DZ3266A1 (fr) 2001-08-02
HUP0204141A2 (hu) 2003-04-28
GT200100016A (es) 2001-10-19
AU2542501A (en) 2001-08-07
IL150545A0 (en) 2003-02-12
BR0107751A (pt) 2002-11-12
IS6443A (is) 2002-06-25
HUP0204141A3 (en) 2005-03-29
SV2002000294A (es) 2002-07-16
SK10632002A3 (sk) 2003-06-03
HN2001000013A (es) 2001-06-18
AR030044A1 (es) 2003-08-13
ZA200205879B (en) 2003-09-29
PA8510701A1 (es) 2002-12-11
CR6706A (es) 2005-04-04
MXPA02007221A (es) 2002-11-29
EE200200405A (et) 2003-12-15
PE20011066A1 (es) 2001-10-22
JP4047010B2 (ja) 2008-02-13

Similar Documents

Publication Publication Date Title
US7053070B2 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
EP1254137A1 (fr) Inhibiteurs de pyrido 2,3-d]pyrimidine-2,7-diamine kinase
CA2329703C (fr) Pyrimidines bicycliques et 3,4-dihydropyrimidines bicycliques, inhibiteurs de proliferation cellulaire
ES2274526T3 (es) Pirido(2,3-d)pirimidinas para inhibir la proliferacion celular mediada por tirosinaquinasa.
KR100421156B1 (ko) 단백질티로신키나제매개세포증식을억제하기위한피리도[2,3-d]피리미딘
ES2301194T3 (es) Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US20040242600A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
US20090312321A1 (en) Compositions and methods for fgf receptor kinases inhibitors
US20040044012A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
CZ2002846A3 (cs) Pteridinony, jako inhibitory kinasy
NZ520962A (en) 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
JP2008519790A (ja) キナーゼ阻害剤としての１，４−置換ピラゾロピリミジン
BG63162B1 (bg) 6-АРИЛ ПИРИДО[2,3-d]ПИРИМИДИНИ И НАФТИРИДИНИ ЗА ИНХИБИРАНЕ НА КЛЕТЪЧНА ПРОЛИФЕРАЦИЯ, МЕДИИРАНА ОТ ПРОТЕИНОВА ТИРОЗИНКИНАЗА
JP6109880B2 (ja) 三環式アザインドール
CN114380822B (zh) β-咔波啉母核的CDKs抑制剂及其制备方法和抗肿瘤的应用
NZ264133A (en) 2-[pyrrolidino, piperidino and hexamethyleneimino] substituted pyrimido pyrimidine derivatives and pharmaceutical compositions
US7323469B2 (en) 7H-pyrrolo[2,3-d]pyrimidine derivatives
OA11554A (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MXPA00010738A (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ZA200006536B (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed